Management of hand-foot syndrome in patients treated with ...

S40
(‘hand-foot’) syndrome: incidence, recognition and management.
American Journal of Clinical Dermatology 1 (4),
225–234.
Ng, J.S., Cameron, D.A., Leonard, R.C., 1994. Infusional 5fluorouracil
in breast cancer. Cancer Treatment Reviews 20
(4), 357–364.
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub,
J.P., Cervantes, G., Fumoleau, P., Jones, P., Liu, W.Y.,
Mauriac, L., Twelves, C., van Hazel, G., Verma, S., Leonard,
R., 2002. Superior survival with capecitabine plus docetaxel
combination therapy in anthracycline-pretreated patients
with advanced breast cancer: phase III trial results. Journal
of Clinical Oncology 20 (12), 2812–2823.
Park, Y.H., Ryoo, B.Y., Lee, H.J., Kim, S.A., Chung, J.H., 2003.
High incidence of severe HFS during capecitabine-docetaxel
combination chemotherapy. Annals of Oncology 14 (11),
1691–1692.
Patt, Y.Z., Liebmann, J., Diamandidis, D., Eckhardt, S.G., Javle,
M., Justice, G.R.W., Keiser, W., Lee, F.C., Miller, W., Lin, E.,
2004. Capecitabine (X) plus irinotecan (XELIRI) as first-line
treatment for metastatic colorectal cancer (MCRC): Final
safety findings from a phase II trial. Proceedings of the
American Society of Clinical Oncology 23, 271 (abstract 3602).
Scheithauer, W., McKendrick Jr., J., Begbie, S., Broner, M.,
Burns, W.I., Burris, H.A., Cassidy, J., Jodrell, D., Koralewski,
P., Levine, E.L., Marschner, N., Maroun, J., Garcia-Alfonso,
P., Tujakowski, J., van Hazel, G., Wong, A., Zaluski, J.,
Twelves, C., for the X-ACT Study Group, 2003. Oral
capecitabine as an alternative to i.v. 5-fluorouracil-based
adjuvant therapy for colon cancer: safety results of a
randomized, phase III trial. Annals of Oncology 14 (12),
1735–1743.
ARTICLE IN PRESS
Y. Lassere, P. Hoff
Sternberg, C.N., Reichardt, P., Holland, M., 2004. Development
of and Clinical experience with capecitabine (Xeloda s ) in the
treatment of solid tumours. European Journal of Oncology
Nursing 8 (Suppl. 1), S4–S15.
Titgan, M.A., 1997. Prevention of palmar-plantar erythrodysesthesia
associated with liposome-encapsulated doxorubicin
by oral dexamethasone. Proceeding of the American Society
of Clinical Oncology 16, 82A (abstract).
Vail, D.M., Chun, R., Thamm, D.H., Garrett, L.D., Cooley, A.J.,
Obradovich, J.E., 1998. Efficacy of pyridoxine to ameliorate
the cutaneous toxicity associated with doxorubicin containing
pegylated (Stealth) liposomes: a randomized, doubleblind
clinical trial using a canine model. Clincal Cancer
Research 4 (6), 1567–1571.
Vakalis, D., Loannides, D., Lazaridou, E., Mattheou-Vakali, G.,
Teknetzis, A., 1998. Acral erythema induced by chemotherapy
with cisplatin. British Journal of Dermatology 139 (4),
750–751.
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley,
D., Pazdur, R., Bassidy, J., Dirix, L., Twelves, C., Allman, D.,
Seitz, J.F., Scholmerich, J., Burger, H.U., Verweij, J., 2000.
Capecitabine, an oral fluoropyrimidine carbamate with
substantial activity in advanced colorectal cancer: results
of a randomized phase II study. Journal of Clinical Oncology
18, 1337–1345.
Vukelja, S.J., Lombard, F.A., James, W.D., 1989. Pyridoxine
therapy for palmar-plantar erythrodysesthesia syndrome.
Annals of Internal Medicine 111 (8), 688–689.
Vukelja, S.J., Baker, W.J., Burris III, H.A., Keeling, J.H., von
Hoff, D., 1993. Pyridoxine therapy for palmar-plantar
erythrodysesthesia associated with Taxotere. Journal of the
National Cancer Institute 85 (17), 1432–1433.